{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:00:47Z","timestamp":1793041247153,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA007288\u201329"],"award-info":[{"award-number":["DA007288\u201329"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["K23AA025399"],"award-info":[{"award-number":["K23AA025399"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.psychres.2021.114347","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T02:43:13Z","timestamp":1639968193000},"page":"114347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["A scoping review of the use of cannabidiol in psychiatric disorders"],"prefix":"10.1016","volume":"308","author":[{"given":"Anna E.","family":"Kirkland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Fadus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci A.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Wilens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Squeglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0001","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/zeb.2017.1541","article-title":"Analysis of the uptake, metabolism, and behavioral effects of cannabinoids on zebrafish larvae","volume":"15","author":"Achenbach","year":"2018","journal-title":"Zebrafish"},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-28689-z","article-title":"Motor neuron development in zebrafish is altered by brief (5-hr) exposures to THC (\u2206 9-tetrahydrocannabinol) or CBD (cannabidiol) during gastrulation","volume":"8","author":"Ahmed","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.psychres.2021.114347_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107452","article-title":"Current legal status of medical marijuana and cannabidiol in the United States","volume":"112","author":"Alharbi","year":"2020","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.psychres.2021.114347_bib0004","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2021.114347_bib0005","unstructured":"Azer, V., Blackledge, J., Charlres, A., Chen, O., Kernan, J., Nadeau, P., Neivert, C., Osborne, J., Rhyee, C., Schenkel, D., 2019. Cowen's collective view of CBD. Cowen's Research."},{"key":"10.1016\/j.psychres.2021.114347_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers","volume":"172","author":"Babalonis","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11920-017-0775-9","article-title":"Cannabis, cannabinoids, and sleep: a review of the literature","volume":"19","author":"Babson","year":"2017","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.psychres.2021.114347_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychires.2020.07.030","article-title":"Efficacy and acceptability of cannabinoids for anxiety disorders in adults: a systematic review & meta-analysis","author":"Bahji","year":"2020","journal-title":"J. Psychiatr. Res"},{"key":"10.1016\/j.psychres.2021.114347_bib0009","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","article-title":"The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors","volume":"119","author":"Bakas","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.psychres.2021.114347_bib0010","first-page":"1","article-title":"Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review","author":"Balachandran","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.psychres.2021.114347_bib0011","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities","volume":"9","author":"Barchel","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.psychres.2021.114347_bib0012","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/jcm8071058","article-title":"The potential of cannabidiol as a treatment for psychosis and addiction: who benefits most? A systematic review","volume":"8","author":"Batalla","year":"2019","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.psychres.2021.114347_bib0013","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2021.114347_bib0014","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of \u0394-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.psychres.2021.114347_bib0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/WCO.0000000000000660","article-title":"Cannabinoid therapy in epilepsy","volume":"32","author":"Billakota","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0016","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.psychres.2021.114347_bib0017","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3389\/fnins.2018.00502","article-title":"Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: from bench research to confirmation in human trials","volume":"12","author":"Bitencourt","year":"2018","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0018","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.psychres.2021.114347_bib0019","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.psychres.2021.114347_bib0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","article-title":"Cannabidiol (CBD) use in psychiatric disorders: a systematic review","volume":"74","author":"Bonaccorso","year":"2019","journal-title":"Neurotoxicology"},{"issue":"17","key":"10.1016\/j.psychres.2021.114347_bib0021","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online","volume":"318","author":"Bonn-Miller","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.psychres.2021.114347_bib0022","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pnpbp.2013.11.017","article-title":"Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or\u2206 9-tetrahydrocannabinol (THC)","volume":"52","author":"Bossong","year":"2014","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2021.114347_bib0023","doi-asserted-by":"crossref","first-page":"e70074","DOI":"10.1371\/journal.pone.0070074","article-title":"Default mode network in the effects of \u03949-Tetrahydrocannabinol (THC) on human executive function","volume":"8","author":"Bossong","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.psychres.2021.114347_bib0024","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cbi.2018.06.008","article-title":"Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos","volume":"291","author":"Brigante","year":"2018","journal-title":"Chem. Biol. Interact."},{"issue":"7","key":"10.1016\/j.psychres.2021.114347_bib0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/jcm8070989","article-title":"Potential adverse drug events and drug\u2013drug interactions with medical and consumer cannabidiol (CBD) use","volume":"8","author":"Brown","year":"2019","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.psychres.2021.114347_bib0026","first-page":"285","article-title":"Pharmacology and legal status of cannabidiol","volume":"56","author":"Brunetti","year":"2020","journal-title":"Ann. dell'Istituto Super. Sanit\u00e0"},{"issue":"14","key":"10.1016\/j.psychres.2021.114347_bib0027","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.3390\/molecules24142583","article-title":"Cannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: a review of possible mechanisms","volume":"24","author":"Calpe-L\u00f3pez","year":"2019","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.psychres.2021.114347_bib0028","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","article-title":"Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats","volume":"199","author":"Campos","year":"2008","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"1607","key":"10.1016\/j.psychres.2021.114347_bib0029","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"issue":"S1","key":"10.1016\/j.psychres.2021.114347_bib0030","doi-asserted-by":"crossref","first-page":"417S","DOI":"10.1002\/j.1552-4604.1981.tb02622.x","article-title":"Hypnotic and antiepileptic effects of cannabidiol","volume":"21","author":"Carlini","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2021.114347_bib0031","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.taap.2018.12.021","article-title":"Multigenerational consequences of early-life cannabinoid exposure in zebrafish","volume":"364","author":"Carty","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0032","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/toxsci\/kfx232","article-title":"Developmental effects of cannabidiol and \u03949-tetrahydrocannabinol in zebrafish","volume":"162","author":"Carty","year":"2018","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0033","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jat.3831","article-title":"The effects of cannabidiol on male reproductive system: a literature review","volume":"40","author":"Carvalho","year":"2020","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.psychres.2021.114347_bib0034","first-page":"1","article-title":"Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials","author":"Chesney","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0035","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/can.2018.0030","article-title":"Regulatory status of cannabidiol in the United States: a perspective","volume":"3","author":"Corroon","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0036","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/can.2018.0006","article-title":"A cross-sectional study of cannabidiol users","volume":"3","author":"Corroon","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0037","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2021.114347_bib0038","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamapsychiatry.2020.3567","article-title":"Urinary tetrahydrocannabinol after 4 weeks of a full-spectrum, high-cannabidiol treatment in an open-label clinical trial","volume":"78","author":"Dahlgren","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0039","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00213-012-2955-y","article-title":"Cannabidiol enhances consolidation of explicit fear extinction in humans","volume":"226","author":"Das","year":"2013","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.psychres.2021.114347_bib0040","doi-asserted-by":"crossref","DOI":"10.1177\/2045125319881916","article-title":"Cannabidiol as a potential treatment for psychosis","volume":"9","author":"Davies","year":"2019","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114347_bib0041","series-title":"Role of Cannabinoid Receptors in Anxiety Disorders, Cannabinoids and the Brain","author":"Degroot","year":"2008"},{"issue":"21","key":"10.1016\/j.psychres.2021.114347_bib0042","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.psychres.2021.114347_bib0043","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"issue":"20","key":"10.1016\/j.psychres.2021.114347_bib0044","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.psychres.2021.114347_bib0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MOL.0b013e32803dbdec","article-title":"Endocannabinoids and the regulation of their levels in health and disease","volume":"18","author":"Di Marzo","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"issue":"14","key":"10.1016\/j.psychres.2021.114347_bib0046","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.psychres.2021.114347_bib0047","first-page":"1","article-title":"Phytochemistry of cannabis sativa L","author":"ElSohly","year":"2017","journal-title":"Phytocannabinoids"},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0048","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"27","author":"Englund","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-52336-w","article-title":"Cannabinoids exacerbate alcohol teratogenesis by a CB1-hedgehog interaction","volume":"9","author":"Fish","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.psychres.2021.114347_bib0050","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3389\/fneur.2019.01145","article-title":"Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use","volume":"10","author":"Fleury-Teixeira","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.psychres.2021.114347_bib0051","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","article-title":"How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review","volume":"107","author":"Freeman","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"10","key":"10.1016\/j.psychres.2021.114347_bib0052","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial","volume":"7","author":"Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psychres.2021.114347_bib0053","article-title":"Medicinal use of cannabis based products and cannabinoids","volume":"365","author":"Freeman","year":"2019","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.psychres.2021.114347_bib0054","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0306-4522(96)00428-9","article-title":"Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain","volume":"77","author":"Glass","year":"1997","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1590\/S1516-44462010000100011","article-title":"Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)","volume":"32","author":"Hallak","year":"2010","journal-title":"Braz. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2021.114347_bib0056","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/npp.2015.367","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis","volume":"41","author":"Haney","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2021.114347_bib0057","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/00498259009046849","article-title":"Metabolites of cannabidiol identified in human urine","volume":"20","author":"Harvey","year":"1990","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0058","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/15504263.2019.1652380","article-title":"The effectiveness of cannabinoids in the treatment of posttraumatic stress disorder (PTSD): a systematic review","volume":"16","author":"Hindocha","year":"2020","journal-title":"J. Dual Diagn."},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-25846-2","article-title":"The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers","volume":"8","author":"Hindocha","year":"2018","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.psychres.2021.114347_bib0060","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/add.14243","article-title":"Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal","volume":"113","author":"Hindocha","year":"2018","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.psychres.2021.114347_bib0061","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","article-title":"Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users","volume":"25","author":"Hindocha","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2021.114347_bib0062","doi-asserted-by":"crossref","unstructured":"Huestis, M., 2005. Pharmacokinetics and Metabolism of the Plant cannabinoids, \u0394 9-tetrahydrocannibinol, Cannabidiol and Cannabinol. Cannabinoids, 657-690.","DOI":"10.1007\/3-540-26573-2_23"},{"issue":"11","key":"10.1016\/j.psychres.2021.114347_bib0063","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0064","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2021.114347_bib0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.schres.2015.01.033","article-title":"A systematic review of the antipsychotic properties of cannabidiol in humans","volume":"162","author":"Iseger","year":"2015","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.psychres.2021.114347_bib0066","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.seizure.2012.03.001","article-title":"Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures","volume":"21","author":"Jones","year":"2012","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42238-019-0012-y","article-title":"The therapeutic role of Cannabidiol in mental health: a systematic review","volume":"2","author":"Khan","year":"2020","journal-title":"J. Cannabis Res."},{"key":"10.1016\/j.psychres.2021.114347_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113246","article-title":"The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis","volume":"291","author":"Kopelli","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2021.114347_bib0069","doi-asserted-by":"crossref","unstructured":"Lachenmeier, D.W., Habel, S., Fischer, B., Herbi, F., Zerbe, Y., Bock, V., de Rezende, T.R., Walch, S.G., Sproll, C., 2019. Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? F1000Research 8.","DOI":"10.12688\/f1000research.19931.1"},{"key":"10.1016\/j.psychres.2021.114347_bib0070","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1684\/epd.2019.1123","article-title":"Pharmacology and drug interactions of cannabinoids","volume":"22","author":"Landmark","year":"2020","journal-title":"Epileptic Disord."},{"issue":"20","key":"10.1016\/j.psychres.2021.114347_bib0071","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2021.114347_bib0072","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/ajt.15398","article-title":"Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus","volume":"19","author":"Leino","year":"2019","journal-title":"Am. J. Transpl."},{"issue":"3","key":"10.1016\/j.psychres.2021.114347_bib0073","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0074","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","article-title":"From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology","volume":"96","author":"Ligresti","year":"2016","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.psychres.2021.114347_bib0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0076","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Machado Bergamaschi","year":"2011","journal-title":"Curr. Drug Saf."},{"issue":"6","key":"10.1016\/j.psychres.2021.114347_bib0077","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3256","article-title":"Clinically significant drug-drug interaction between methadone and cannabidiol","volume":"145","author":"Madden","year":"2020","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.psychres.2021.114347_bib0078","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/ADM.0000000000000118","article-title":"Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans","volume":"9","author":"Manini","year":"2015","journal-title":"J. Addict. Med."},{"issue":"5","key":"10.1016\/j.psychres.2021.114347_bib0079","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","article-title":"Meta-analysis of the association between the level of cannabis use and risk of psychosis","volume":"42","author":"Marconi","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2021.114347_bib0080","first-page":"1","article-title":"Differentiating full-spectrum hemp extracts from CBD isolates: implications for policy, safety and science","author":"Marinotti","year":"2020","journal-title":"J. Diet. Suppl."},{"key":"10.1016\/j.psychres.2021.114347_bib0081","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","article-title":"Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders","volume":"10","author":"Masataka","year":"2019","journal-title":"Front. Psychol."},{"issue":"3","key":"10.1016\/j.psychres.2021.114347_bib0082","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114347_bib0083","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.psychres.2021.114347_bib0084","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0085","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1192\/bjp.bp.107.046649","article-title":"Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis","volume":"192","author":"Morgan","year":"2008","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2021.114347_bib0086","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings","volume":"38","author":"Morgan","year":"2013","journal-title":"Addict. Behav."},{"issue":"9","key":"10.1016\/j.psychres.2021.114347_bib0087","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/npp.2010.58","article-title":"Cannabidiol attenuates the appetitive effects of \u0394 9-tetrahydrocannabinol in humans smoking their chosen cannabis","volume":"35","author":"Morgan","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0088","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1192\/bjp.bp.110.077503","article-title":"Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study","volume":"197","author":"Morgan","year":"2010","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2021.114347_bib0089","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000447013","article-title":"Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial","volume":"85","author":"Nordahl","year":"2016","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.psychres.2021.114347_bib0090","first-page":"1","article-title":"Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis","author":"O\u2019Neill","year":"2020","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0091","first-page":"1","article-title":"The role of the endocannabinoid system in female reproductive tissues","volume":"12","author":"O\u2019Llenecia","year":"2019","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.psychres.2021.114347_bib0092","doi-asserted-by":"crossref","DOI":"10.1177\/02698811211001107","article-title":"Cannabidiol modulation of hippocampal glutamate in early psychosis","author":"O'Neill","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114347_bib0093","unstructured":"Organization, W.H., 2018. Cannabidiol (CBD) critical review report, Geneva."},{"key":"10.1016\/j.psychres.2021.114347_bib0094","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.neubiorev.2016.11.012","article-title":"A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia","volume":"72","author":"Osborne","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.psychres.2021.114347_bib0095","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3389\/fneur.2018.00759","article-title":"Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis","volume":"9","author":"Pamplona","year":"2018","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.psychres.2021.114347_bib0096","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrn4004","article-title":"Endocannabinoid signalling in reward and addiction","volume":"16","author":"Parsons","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.psychres.2021.114347_bib0097","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03b49-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0098","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0706743719895195","article-title":"Cannabidiol as a treatment for mood disorders: a systematic review","volume":"65","author":"Pinto","year":"2020","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2021.114347_bib0099","unstructured":"Poll, G., 2020. 14% of Americans Say They Use CBD Products. . Gallup."},{"issue":"9","key":"10.1016\/j.psychres.2021.114347_bib0100","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/0269881119858306","article-title":"The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD)","volume":"33","author":"Pretzsch","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.114347_bib0101","doi-asserted-by":"crossref","unstructured":"Prud'homme, M., Cata, R., Jutras-Aswad, D., 2015. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Substance abuse: research and treatment 9, SART. S25081.","DOI":"10.4137\/SART.S25081"},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0102","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14740338.2017.1397128","article-title":"Drug-drug interactions as a result of co-administering \u03949-THC and CBD with other psychotropic agents","volume":"17","author":"Rong","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.psychres.2021.114347_bib0103","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","article-title":"Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial","volume":"88","author":"Schoedel","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.psychres.2021.114347_bib0104","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2215-0366(15)00363-6","article-title":"Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis","volume":"3","author":"Schoeler","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.psychres.2021.114347_bib0105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.schres.2011.04.017","article-title":"Cannabis with high cannabidiol content is associated with fewer psychotic experiences","volume":"130","author":"Schubart","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2021.114347_bib0106","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X20947896","article-title":"Drug-drug interactions between cannabidiol and lithium","volume":"7","author":"Singh","year":"2020","journal-title":"Child Neurol. Open"},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0107","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.japh.2019.11.008","article-title":"Use of cannabidiol in anxiety and anxiety-related disorders","volume":"60","author":"Skelley","year":"2020","journal-title":"J. Am. Pharm. Assoc."},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","article-title":"A randomised controlled trial of vaporised \u0394 9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects","volume":"269","author":"Solowij","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2021.114347_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107937","article-title":"Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users","author":"Spindle","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.psychres.2021.114347_bib0110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuroscience.2017.07.018","article-title":"Effects of cannabinoid drugs on aversive or rewarding drug-associated memory extinction and reconsolidation","volume":"370","author":"Stern","year":"2018","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0111","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.psychres.2021.114347_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106938","article-title":"Abrupt withdrawal of cannabidiol (CBD): a randomized trial","volume":"104","author":"Taylor","year":"2020","journal-title":"Epilepsy Behav."},{"issue":"11","key":"10.1016\/j.psychres.2021.114347_bib0113","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.psychres.2021.114347_bib0114","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bph.14440","article-title":"Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors","volume":"176","author":"Tham","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.psychres.2021.114347_bib0115","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.psychres.2021.114347_bib0116","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190768","article-title":"Nabiximols combined with motivational enhancement\/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial","volume":"13","author":"Trigo","year":"2018","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0118","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/ADM.0000000000000229","article-title":"Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence: a case series","volume":"10","author":"Trigo","year":"2016","journal-title":"J. Addict. Med."},{"issue":"4","key":"10.1016\/j.psychres.2021.114347_bib0119","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/acer.13964","article-title":"Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review","volume":"43","author":"Turna","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.psychres.2021.114347_bib0120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1089\/can.2015.0012","article-title":"Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy","volume":"1","author":"Ujv\u00e1ry","year":"2015","journal-title":"Cannabis Cannabinoid Res."},{"issue":"2","key":"10.1016\/j.psychres.2021.114347_bib0121","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jat\/bkx012","article-title":"Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes","volume":"41","author":"Vandrey","year":"2017","journal-title":"J. Anal. Toxicol."},{"issue":"10","key":"10.1016\/j.psychres.2021.114347_bib0122","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/jcph.1634","article-title":"A phase 2, double-blind, placebo-controlled trial to investigate potential drug-drug interactions between cannabidiol and clobazam","volume":"60","author":"VanLandingham","year":"2020","journal-title":"J. Clin. Pharmacol"},{"issue":"10","key":"10.1016\/j.psychres.2021.114347_bib0123","first-page":"463","article-title":"Cannabidiol-therapeutic and legal aspects","volume":"75","author":"Vlad","year":"2020","journal-title":"Die Pharm. Int. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.psychres.2021.114347_bib0124","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.2071","article-title":"Cannabidiol and abnormal liver chemistries in healthy adults: results of a phase 1 clinical trial","volume":"109","author":"Watkins","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.psychres.2021.114347_bib0125","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/jcph.1387","article-title":"A review of human studies assessing cannabidiol's (CBD) therapeutic actions and potential","volume":"59","author":"White","year":"2019","journal-title":"J. Clin. Pharmacol."},{"issue":"32","key":"10.1016\/j.psychres.2021.114347_bib0126","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.2174\/138161212802884744","article-title":"The endocannabinoid system and schizophrenia: integration of evidence","volume":"18","author":"Zamberletti","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.psychres.2021.114347_bib0127","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br. J. Pharmacol."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178121006417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178121006417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:50:13Z","timestamp":1759038613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178121006417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":127,"alternative-id":["S0165178121006417"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2021.114347","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A scoping review of the use of cannabidiol in psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2021.114347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114347"}}